Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer

International Journal of Cancer

Volumn 127, Issue 3, 2010, Pages 612-621

  Dobrzycka, Bozena ^a   Terlikowski, Slawomir J ^a   Mazurek, Andrzej ^a   Kowalczuk, Oksana ^a   Niklinska, Wieslawa ^a   Chyczewski, Lech ^a   Kulikowski, Marek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CIRCULATING FREE DNA; DNA; K RAS PROTEIN; P53 ANTIBODY; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY;

AGED; ANTIBODIES; BASE SEQUENCE; DNA; DNA PRIMERS; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, RAS; HUMANS; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954438948     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25077     Document Type: Article

References (67)

1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, et al., eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute, 2009. Available at: http://seer.cancer.gov/csr/1975-2006/.
2. Stewart BW, Kleihues P. World cancer report. Lyon: IARC Press, 2003.
3. National Cancer Registry. The Maria Sklodowska - Curie Memorial Cancer Center, Department of Epidemiology and Cancer Prevention, National Cancer Registry, 2004. Available at: http://epid.coi.waw.pl/krn.
4. Allgayer H, Fulda S. An introduction to molecular targeted therapy of cancer. Adv Med Sci 2008;53:130-38.
5. Blum HE. Molecular therapy and prevention of liver diseases. Adv Med Sci 2007;52:29-36.
6. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366:491-505.
7. Lundgren C, Auer G, Frankendal B, Moberger B, Nilsson B, Nordström B. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 2002;12:110-18.
8. Mangili G, Montoli S, De Marzi P, Sassi I, Aletti G, Aletti G, Taccagni G. The role of DNA ploidy in postoperative management of stage I endometrial cancer. Ann Oncol 2008;19:1278-83.
9. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 2007;46:26-32.
10. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-23.
11. Abal M, Planaguma J, Gil-Moreno A, Monge M, Gonzalez M, Baro T, Garcia A, Castellvi J, Ramon Y, Cajal S, Xercavins J, Alameda F, et al. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol 2006;21:197-204. (Pubitemid 43033728)
12. Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklińska W, Chyczewski L, Kulikowski M. Mutations of the K-ras oncogene in endometrial hyperplasia and carcinoma. Folia Histochem Cytobiol 2009;47:65-8.
13. Barbati A, Mariani L, Porpora MG, Anceschi M, Collini P, Lauro V, Cosmi EV. Serum evaluation of P53 protein in patients with gynaecological cancer. Anticancer Res 2000;20:1033-5. (Pubitemid 30240672)
14. Ben-Hur H, Berman V, Sandler B, Smirnoff P, Gurevich P, Open M, Zusman I. Serological and immunohistochemical determinations of p53 protein in diagnosis of endometrial cancer: a comparative study. Eur J Gynaecol Oncol 1997;18:400-6. (Pubitemid 27437752)
15. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002;110:673-89.
16. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8.
17. Gadducci A, Ferdeghini M, Buttitta F, Fanucchi A, Annicchiarico C, Prontera C, Bevilacqua G, Genazzani AR. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. Anticancer Res 1996;16:3519-23. (Pubitemid 27085006)
18. Lenczewski A, Terlikowski S, Dobrzycka B, Famulski W, Koda M, Sulkowski S, Kulikowski M. Tissue expression of p53 protein and anti-p53 antibodies in serum of patients with carcinoma of the uterine cervix. Gin Onkol 2004;2:174-80.
19. Marx D, Frey M, Zentgraf H, Adelssen G, Schauer A, Kuhn W, Meden H. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer. Cancer Detect Prev 2001;25:117-22.
20. Yamazawa K, Shimada H, Hirai M, Hirashiki K, Ochiai T, Ishikura H, Shozu M, Isaka K. Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer. Am J Obstet Gynecol 2007;197:505.e1-505.e7.
21. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50. (Pubitemid 8051621)
22. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007;635:105-17.
23. Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E, Dalay N. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med 2008;46:311-17.
24. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006;24:4270-6.
25. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW, Shih IEM. Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966-8. (Pubitemid 36917913)
26. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007;39:46-54.
27. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, Rice JM. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991;51:5308-14.
28. Liao X, Siu MK, Chan KY, Wong ES, Ngan HY, Chan QK, Li AS, Khoo US, Cheung AN. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer 2008;123:296-302.
29. Goodfellow PJ. Molecular genetics of uterine malignancies. In: Cukos G, Rubin SC, eds. Cancer of the uterus. New York: Marcel Dekker, 2005. 1-19.
30. Alexander-Sefre F, Salvesen HB, Ryan A, Singh N, Akslen LA, MacDonald N, Wilbanks G, Jacobs IJ. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecol Oncol 2003;91:218-25.
31. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
32. Fujimoto I, Shimizu Y, Hirai Y, Chen JT, Teshima H, Hasumi K, Masubuchi K, Takahashi M. Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol 1993;48:196-202. (Pubitemid 23075172)
33. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992;52:2777-88.
34. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, Silverberg SG, Garrett CT. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient. Gynecol Oncol 1996;63:238-46.
35. Lüttges J, Neumann S, Jesnowski R, Borries V, Löhr M, Klöppel G. Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status. Pancreas 2003;27:e57-e62.
36. Mammas IN, Zafiropoulos A, Spandidos DA. Involvement of the ras genes in female genital tract cancer. Int J Oncol 2005;26:1241-55.
37. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colás E, Llauradó M, Alazzouzi H, Planagumá J, Lohmann MA, Garcia J, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 2008;108:221-9.
38. Wooster R, Futreal AP, Stratton MR. Sequencing analysis of BRAF mutations in human cancers. Methods Enzymol 2006;407:218-24.
39. Feng YZ, Shiozawa T, Horiuchi A, Shih HC, Miyamoto T, Kashima H, Suzuki A, Nikaido T, Konishi I. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas. Virchows Arch 2005;447:816-22.
40. Pijnenborg JM, van de Broek L, Dam de Veen GC, Roemen GM, de Haan J, van Engeland M, Voncken JW, Groothuis PG. TP53 overexpression in recurrent endometrial carcinoma. Gynecol Oncol 2006;100:397-404.
41. Erkanli S, Eren F, Pekin S, Bagis T. BCL-2 and P53 expression in endometrial carcinoma. J Exp Clin Cancer Res 2004;23:97-103. (Pubitemid 38552604)
42. Ozalp S, Yalcin OT, Tanir HM, Kabukcuoglu S, Erol G. p53 overexpression as a prognostic indicator in endometrial carcinoma. Eur J Gynaecol Oncol 2003;24:275-8.
43. Terlikowski S, Lenczewski A, Famulski W, Sulkowska M, Dobrzycka B, Stasiak-Barmuta A, Kulikowski M. Patterns of immunohistochemical staining for p53 expression in hyperplastic endometrium and adenocarcinoma. Folia Histochem Cytobiol 2001;39 (Suppl 2):195-6. (Pubitemid 34070818)
44. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Jr, Berchuck A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.
45. Inoue M. Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 2001;11:339-48.
46. Coomber D, Hawkins NJ, Clark M, Meagher A, Ward RL. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol 1996;122:757-62. (Pubitemid 26393245)
47. Vogl FD, Frey M, Kreienberg R, Runnebaum IB. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000;83:1338-43.
48. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.
49. Zanetti-Dällenbach RA, Schmid S, Wight E, Holzgreve W, Ladewing A, Hahn S, Zhong XY. Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers 2007;22:95-9. (Pubitemid 47062213)
50. Tong YK, Lo YM. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta 2006;363:187-96.
51. Chen Z, Fadiel A, Naftolin F, Eichenbaum KD, Xia Y. Circulation DNA: biological implications for cancer metastasis and immunology. Medical Hypotheses 2005;65:956-61.
52. Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 2005;11:1394-9.
53. Tamkovich SN, Laktionov PP, Rykova EY, Vlassov VV. Simple and rapid procedure suitable for quantitative isolation of low and high molecular weight extracellular nucleic acids. Nucleosides Nucleotides Nucleic Acids 2004;23:873-7.
54. Farias E, Ranuncolo S, Cresta C, Specterman S, Armanasco E, Varela M, Lastiri J, Pallotta MG, Bal de Kier Joffe E, Puricelli L. Plasma metalloproteinase is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 2000;89:389-94.
55. Ziegler A, Zangemeister WU, Stahel RA. Circulating DNA a new diagnostic gold mine? Cancer Treat Rev 2002;28:255-71.
56. Castells A, Puig P, Móra J, Boadas J, Boix L, Urgell E, Solé M, Capellà G, Lluís F, Fernández-Cruz L, Navarro S, Farré A. Kras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999;17:578-84.
57. de Kok JB, van Solinge WW, Ruers TJ, Roelofs RW, van Muijen GN, Willems JL, Swinkels DW. Detection of tumour DNA in serum of colorectal cancer patients. Scand J Clin Lab Invest 1997;57:601-4.
58. Chen X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub E, Stroun M, Anker P. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999;5:2297-2303. (Pubitemid 29437305)
59. Cho-Chung YS. Autoantibody biomarkers in the detection of cancer. Biochim Biophys Acta 2006;1762:587-91.
60. Høgdall EV, Høgdall CK, Blaakaer J, Heegaard NH, Glud E, Christensen L, Bock JE, Nørgaard-Pedersen B, Wiik A, Kjaer SK. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS 2002;110:545-53.
61. Hussain SP, Hollstein MH, Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann N Y Acad Sci 2000;919:79-85.
62. Angelopoulou K, Yu H, Bharaj B, Giai M, Diamandis EP. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clin Biochem 2000;33:53-62.
63. Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24:762-8.
64. Regele S, Vogl FD, Kohler T, Kreienberg R, Runnebaum IB. p53 autoantibodies can be indicative of the development of breast cancer relapse. Anticancer Res 2003;23:761-4.
65. Cai HY, Wang XH, Tian Y, Gao LY, Zhang LJ, Zhang ZY. Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma. World J Gastroenterol 2008;14:4082-6.
66. Numa F, Umayahara K, Suehiro Y, Hirakawa H, Nawata S, Suminami Y, Oga A, Ito T, Sasaki K, Kato H. Serum anti-p53 antibodies in uterine and ovarian cancer: association with DNA sequence copy number abnormalities. Tumour Biol 2001;22:162-8.
67. Sobti RC, Parashar K, Kaur R, Capalash N. Detection of human papillomavirus DNA, serum p53, and p53 antibodies in patients with cervical cancer. J Environ Pathol Toxicol Oncol 2002;21:79-85. (Pubitemid 34258229)